Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
Cancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a pillar of cancer therapy, access in these settings lags well behind that in high-income countries (H...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e011258.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319309058244608 |
|---|---|
| author | T Peter Kingham Innocent Adoubi Avery D Posey Ahmad A Tarhini David R Kaufman Jyoti Bajpai Solmaz Sahebjam Mauricio Burotto Verna Vanderpuye Thomas S Uldrick Olufunmilayo I Olopade Thomas A Odeny Wilfred Ngwa Jennifer Dent Micaella Jorge Nora Sobrevilla Huwaida Bulhan Gideon T Dosunmu Lilian Ekpo Satish Gopal Manuel R Espinoza-Gutarra N’da Marcelin Homian Clarissa Mathias Nixon Niyonzima Blaise Nkegoum Regina Switzer |
| author_facet | T Peter Kingham Innocent Adoubi Avery D Posey Ahmad A Tarhini David R Kaufman Jyoti Bajpai Solmaz Sahebjam Mauricio Burotto Verna Vanderpuye Thomas S Uldrick Olufunmilayo I Olopade Thomas A Odeny Wilfred Ngwa Jennifer Dent Micaella Jorge Nora Sobrevilla Huwaida Bulhan Gideon T Dosunmu Lilian Ekpo Satish Gopal Manuel R Espinoza-Gutarra N’da Marcelin Homian Clarissa Mathias Nixon Niyonzima Blaise Nkegoum Regina Switzer |
| author_sort | T Peter Kingham |
| collection | DOAJ |
| description | Cancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a pillar of cancer therapy, access in these settings lags well behind that in high-income countries (HICs). Increasing the evaluation of ICIs through local clinical trials and demonstration projects, and inclusion in multinational clinical trials is the first step to improving access. In particular, the epidemiology and clinical presentation of cancer in LMICs is often distinct from that in HICs, and the impact of immune checkpoint blockade in these settings is understudied. Moreover, unique patterns of comorbidities, environmental factors, genetic diversity, and paucity of supportive infrastructure may all impact the risk-benefit and outcomes of cancer immunotherapy treatment. Local clinical trials not only directly impact the strengthening of infrastructure but also provide local authorities with better insight into the health economic benefit of cancer immunotherapy, giving impetus to adoption and reimbursement efforts. More local, regional, and multinational collaborative efforts are needed to speed up the evaluation, access, and adoption of ICIs throughout the developing world. |
| format | Article |
| id | doaj-art-49f6b1dde2d64d7ea89097aa5503addb |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-49f6b1dde2d64d7ea89097aa5503addb2025-08-20T03:50:31ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-06-0113610.1136/jitc-2024-011258Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committeeT Peter Kingham0Innocent Adoubi1Avery D Posey2Ahmad A Tarhini3David R Kaufman4Jyoti Bajpai5Solmaz Sahebjam6Mauricio Burotto7Verna Vanderpuye8Thomas S Uldrick9Olufunmilayo I Olopade10Thomas A Odeny11Wilfred Ngwa12Jennifer Dent13Micaella Jorge14Nora Sobrevilla15Huwaida Bulhan16Gideon T Dosunmu17Lilian Ekpo18Satish Gopal19Manuel R Espinoza-Gutarra20N’da Marcelin Homian21Clarissa Mathias22Nixon Niyonzima23Blaise Nkegoum24Regina Switzer25Memorial Sloan Kettering Cancer Center, New York, New York, USAUniversity Teaching Hospital of Treichville, Abidjan, Côte d’IvoireUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USACutaneous Oncology and Immunology, Moffitt Cancer Center, Tampa, Florida, USAThird Rock Ventures LLC, Boston, Massachusetts, USAApollo Hospital Navi Mumbai and Maharashtra, Navi Mumbai, IndiaJohns Hopkins Medicine, Baltimore, Maryland, USABradford Hill Clinical Research Center, Santiago, ChileNational Center for Radiotherapy, Oncology and Nuclear Medicine, Korlebu Teaching Hospital, Accra, GhanaRegeneron Pharmaceuticals, Tarrytown, New York, USAThe University of Chicago, Chicago, Illinois, USAWashington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri, USAJohns Hopkins Medicine, Baltimore, Maryland, USABIO Ventures for Global Health, Seattle, Washington, USABIO Ventures for Global Health, Seattle, Washington, USAInstituto Nacional de Cancerología, Mexico City, MexicoRoche, Nairobi, KenyaThe University of Chicago, Chicago, Illinois, USANSIA-LUTH Cancer Centre, Lagos, NigeriaNCI Center for Global Health, Rockville, Maryland, USAThe University of Alabama at Birmingham, Birmingham, Alabama, USAUniversity Hospital Medical Center at Treichville (CHU Treichville), Abidjan, Côte d’IvoireOC Oncoclínicas NOB Ondina, Salvador, BrazilUganda Cancer Institute, Kampala, UgandaUniversity Hospital Center Yaounde, Yaoundé, CameroonBeOne Medicines, Ltd, Chicago, Illinois, USACancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a pillar of cancer therapy, access in these settings lags well behind that in high-income countries (HICs). Increasing the evaluation of ICIs through local clinical trials and demonstration projects, and inclusion in multinational clinical trials is the first step to improving access. In particular, the epidemiology and clinical presentation of cancer in LMICs is often distinct from that in HICs, and the impact of immune checkpoint blockade in these settings is understudied. Moreover, unique patterns of comorbidities, environmental factors, genetic diversity, and paucity of supportive infrastructure may all impact the risk-benefit and outcomes of cancer immunotherapy treatment. Local clinical trials not only directly impact the strengthening of infrastructure but also provide local authorities with better insight into the health economic benefit of cancer immunotherapy, giving impetus to adoption and reimbursement efforts. More local, regional, and multinational collaborative efforts are needed to speed up the evaluation, access, and adoption of ICIs throughout the developing world.https://jitc.bmj.com/content/13/6/e011258.full |
| spellingShingle | T Peter Kingham Innocent Adoubi Avery D Posey Ahmad A Tarhini David R Kaufman Jyoti Bajpai Solmaz Sahebjam Mauricio Burotto Verna Vanderpuye Thomas S Uldrick Olufunmilayo I Olopade Thomas A Odeny Wilfred Ngwa Jennifer Dent Micaella Jorge Nora Sobrevilla Huwaida Bulhan Gideon T Dosunmu Lilian Ekpo Satish Gopal Manuel R Espinoza-Gutarra N’da Marcelin Homian Clarissa Mathias Nixon Niyonzima Blaise Nkegoum Regina Switzer Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee Journal for ImmunoTherapy of Cancer |
| title | Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee |
| title_full | Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee |
| title_fullStr | Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee |
| title_full_unstemmed | Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee |
| title_short | Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee |
| title_sort | cancer immunotherapy clinical trials to support urgently needed access in low and middle income countries a report from the sitc global access and impact committee |
| url | https://jitc.bmj.com/content/13/6/e011258.full |
| work_keys_str_mv | AT tpeterkingham cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT innocentadoubi cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT averydposey cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT ahmadatarhini cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT davidrkaufman cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT jyotibajpai cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT solmazsahebjam cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT mauricioburotto cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT vernavanderpuye cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT thomassuldrick cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT olufunmilayoiolopade cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT thomasaodeny cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT wilfredngwa cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT jenniferdent cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT micaellajorge cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT norasobrevilla cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT huwaidabulhan cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT gideontdosunmu cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT lilianekpo cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT satishgopal cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT manuelrespinozagutarra cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT ndamarcelinhomian cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT clarissamathias cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT nixonniyonzima cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT blaisenkegoum cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee AT reginaswitzer cancerimmunotherapyclinicaltrialstosupporturgentlyneededaccessinlowandmiddleincomecountriesareportfromthesitcglobalaccessandimpactcommittee |